| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
|
J Clin Oncol
|
2006
|
2.27
|
|
2
|
siRNA vs. shRNA: similarities and differences.
|
Adv Drug Deliv Rev
|
2009
|
1.91
|
|
3
|
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
|
J Clin Oncol
|
2005
|
1.83
|
|
4
|
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
|
Mol Ther
|
2005
|
1.81
|
|
5
|
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
|
Mol Ther
|
2005
|
1.53
|
|
6
|
Stathmin 1: a novel therapeutic target for anticancer activity.
|
Expert Rev Anticancer Ther
|
2008
|
1.51
|
|
7
|
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.
|
Mol Ther
|
2009
|
1.50
|
|
8
|
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
|
Cancer Gene Ther
|
2003
|
1.40
|
|
9
|
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
|
Cancer
|
2012
|
1.36
|
|
10
|
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review).
|
Int J Oncol
|
2007
|
1.34
|
|
11
|
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
|
Clin Cancer Res
|
2011
|
1.27
|
|
12
|
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.
|
Gastrointest Endosc
|
2012
|
1.19
|
|
13
|
Oncolytic viruses for induction of anti-tumor immunity.
|
Curr Pharm Biotechnol
|
2012
|
1.18
|
|
14
|
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.
|
Toxicol Appl Pharmacol
|
2006
|
1.12
|
|
15
|
RNA interference and cancer therapy.
|
Pharm Res
|
2011
|
1.11
|
|
16
|
TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up.
|
Ann Surg Oncol
|
2005
|
1.02
|
|
17
|
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.
|
Clin Cancer Res
|
2004
|
1.00
|
|
18
|
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine.
|
Clin Cancer Res
|
2011
|
0.99
|
|
19
|
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
0.97
|
|
20
|
Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex.
|
Hum Gene Ther
|
2011
|
0.93
|
|
21
|
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.
|
Cancer Invest
|
2006
|
0.90
|
|
22
|
Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy.
|
J Gene Med
|
2010
|
0.90
|
|
23
|
PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform.
|
PLoS One
|
2012
|
0.88
|
|
24
|
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.
|
Mol Ther
|
2006
|
0.88
|
|
25
|
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
|
Gastrointest Endosc
|
2012
|
0.87
|
|
26
|
Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
|
Cancer Invest
|
2005
|
0.87
|
|
27
|
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver.
|
Oncology
|
2014
|
0.86
|
|
28
|
In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein.
|
DNA Cell Biol
|
2011
|
0.85
|
|
29
|
RNA interference and personalized cancer therapy.
|
Discov Med
|
2013
|
0.83
|
|
30
|
Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2).
|
Gene Regul Syst Bio
|
2008
|
0.79
|
|
31
|
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
|
Clin Cancer Res
|
2005
|
0.79
|
|
32
|
Systemic therapeutic gene delivery for cancer: crafting Paris' arrow.
|
Curr Gene Ther
|
2009
|
0.79
|
|
33
|
Reversible masking using low-molecular-weight neutral lipids to achieve optimal-targeted delivery.
|
J Drug Deliv
|
2012
|
0.78
|
|
34
|
Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancers.
|
Am J Surg
|
2002
|
0.77
|
|
35
|
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease.
|
ISRN Oncol
|
2012
|
0.77
|
|
36
|
Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2.
|
Gene Regul Syst Bio
|
2009
|
0.76
|
|
37
|
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.
|
Semin Radiat Oncol
|
2002
|
0.76
|
|
38
|
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
|
Invest New Drugs
|
2014
|
0.76
|
|
39
|
Letter to the editor: Does dicer expression affect shRNA processing?
|
Gene Regul Syst Bio
|
2009
|
0.75
|
|
40
|
Procoagulant inhibitory properties of paclitaxel poliglumex.
|
Int J Gen Med
|
2010
|
0.75
|
|
41
|
Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles.
|
J Genet Syndr Gene Ther
|
2011
|
0.75
|
|
42
|
Enhanced oncolytic potency of replicative adenovirus expressing p53.
|
Drug Resist Updat
|
2003
|
0.75
|
|
43
|
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
|
J Pediatr Hematol Oncol
|
2017
|
0.75
|
|
44
|
Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy.
|
Semin Oncol
|
2003
|
0.75
|
|
45
|
Individualised cancer therapeutics: dream or reality? Therapeutics construction.
|
Expert Opin Biol Ther
|
2005
|
0.75
|
|
46
|
Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application.
|
Methods Mol Biol
|
2013
|
0.75
|
|
47
|
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
|
J Oncol Manag
|
2005
|
0.75
|